Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.

NCT05416229 is registered in ClinicalTrials.gov with Anders Fink-Jensen, MD, DMSci as lead sponsor.

NCT NCT05416229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05416229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.
Lead sponsor
Anders Fink-Jensen, MD, DMSci
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2023
Completion date
December 22, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder